Block-replace ATD regimen prevents Graves’ disease relapse better than titration regimen
In patients with Graves’ disease (GD), the block-replace antithyroid drug (ATD) regimen leads to a lower relapse rate than the titration regimen, according to a study. Factors such as younger age, larger goiter size or thyroid volume, and the higher free triiodothyronine or free thyroxine levels in the diagnosing phase are tied to a higher risk of relapse.
